The Na 1 /glucose cotransporter 1 (SGLT1) is responsible for glucose uptake in intestinal epithelial cells. It has been shown that the intestinal SGLT1 level is significantly increased in diabetic individuals and positively correlated with the pathogenesis of diabetes. The development of targeted therapeutics that can reduce the intestinal SGLT1 expression level is, therefore, important. In this study, we showed that ginsenoside Rg1 effectively decreased intestinal glucose uptake through inhibition of SGLT1 gene expression in vivo and in vitro. Transient transfection analysis of the SGLT1 promoter revealed an essential cAMP response element (CRE) that confers the Rg1-mediated inhibition of SGLT1 gene expression. Chromatin immunoprecipitation assay and targeted CRE-binding protein (CREB) silencing demonstrated that Rg1 reduced the promoter binding of CREB and CREB binding protein associated with an inactivated chromatin status. In addition, further studies showed that the epidermal growth factor receptor (EGFR) signaling pathway also plays an essential role in the inhibitory effect of Rg1; taken together, our study demonstrates the involvement of the EGFR-CREB signaling pathway in the Rg1-mediated downregulation of SGLT1 expression, which offers a potential strategy in the development of antihyperglycemic and antidiabetic treatments.
Introduction
Na 1 /glucose cotransporter 1 (SGLT1) is expressed in the brush border membrane of intestinal epithelial cells (IECs) and plays a central role in the active uptake of glucose (Wood and Trayhurn, 2003; Drozdowski and Thomson, 2006) . Once inside the enterocytes, these sugars are either metabolized or diffused out of the cell through the facilitative glucose transporter 2 (GLUT2), located on the basolateral membrane. Hyperglycemia is a metabolic hallmark associated with type 2 diabetes, and it is caused by pancreatic b-cell dysfunction (Brownlee, 2005) . Clinical studies have indicated increased SGLT1 mRNA and protein levels in patients with diabetes (Dyer et al., 2002) . It has also been described that the intestinal absorption of glucose was markedly enhanced in mice with experimental diabetes (Dyer et al., 1997; Fujita et al., 1998) . These observations suggest the crucial role of SGLT in accelerated intestinal glucose absorption in patients with diabetes. Thus, accumulating evidence has indicated that the pharmacological reduction of SGLT1-mediated glucose uptake can be an effective therapeutic approach for diabetes (Shibazaki et al., 2012; Powell et al., 2013) .
Ginseng is a highly valued herb in Asian countries (Leung and Wong, 2010) . Ginsenoside Rg1, with sugar moieties at the C6 and C20 positions (Fig. 1A) , is an active compound responsible for many of ginseng's pharmacological activities. One of the notable pharmacological effects of ginseng is its hypoglycemic activity, which is supported by many clinical studies (Sotaniemi et al., 1995; Vuksan et al., 2000) . Ginseng extract has been shown to lower blood glucose level in both diabetic and glucose-loaded healthy animals (Ohnishi et al., 1996) . The proposed mechanisms for the hypoglycemic effect of ginseng including enhanced hepatic glucose uptake (Ohnishi et al., 1996) , enhanced insulin secretion and sensitivity (Zhang et al., 2008; Gao et al., 2013) , enhanced glucagon-like peptide-1 secretion , enhanced lipid metabolism (Xie et al., 2005) , facilitated immune homeostasis (Hong et al., 2012) , reduced food intake and body weight (Attele et al., 2002; Xiong et al., 2010) , or a combination of these modes (Zhang et al., 2008; Hong et al., 2012; Gao et al., 2013) .
Previously, Rg1 was found to inhibit glucose uptake and SGLT1 gene expression in differentiated human intestinal Caco-2 cells (Chang et al., 2007) . In the present study, we explored the regulatory mechanism underlying Rg1-mediated reduction in SGLT1 gene expression using in vivo mouse and in vitro human intestinal cell models. We identified and characterized a cAMP response element (CRE) in the SGLT1 promoter that is required for Rg1-induced inhibition of human intestinal SGLT1 gene expression. Our findings provide valuable insight into the mode of action in Rg1-mediated reduction of SGLT1 expression in IECs, suggesting a potential therapeutic application for diabetes.
Materials and Methods
Materials and Compounds. Rg1 (NuLiv Science, Inc., Walnut, CA) was dissolved in 0.01% dimethylsulfoxide for cellular experiment.
D-[
14 C]-a-methylglucopyranoside (AMG) was obtained from American Radiolabeled Chemicals (St. Louis, MO). Primary antibodies for CREbinding protein (CREB), phosphorylated CREB, CREB binding protein (CBP), epidermal growth factor (EGF) receptor (EGFR), phosphorylated-EGFR, acetyl-histone H3, dimethylation on lysine 4 of histone H3, dimethylation on lysine 9 of histone H3, HNF-1, SGLT1, Sp1, and b-actin were purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
Animal Model. Male C57BL/6 mice (6-8 weeks of age) were obtained from the BioLASCO Experimental Animal Center (Taipei, Taiwan) and housed in temperature-controlled ventilated cages on a 12/12-hour light/dark cycle (22 6 2°C, 30%-70% humidity) at the animal center of the National Defense Medical Center. The mice were randomly separated into control or Rg1 groups and orally treated by gavage with 1% dimethylsulfoxide or Rg1 (20 mg/kg, dissolved in 1% dimethylsulfoxide), respectively (Lee et al., 2005) . The mice were sacrificed after 30 hours of drug treatment. The animal tissues were then collected for subsequent analysis. All animal studies were performed with the approval of the Institutional Animal Care and Use Committee of the National Defense Medical Center.
Cell Culture. The human intestinal Caco-2 cells (ATCC, Rockville, MD) were cultured in 37°C, 5% CO 2 , 95% humidity in Dulbecco's modified Eagle's medium supplemented with 4.5 g/l glucose, 0.2 mM glutamine, 3.7% sodium bicarbonate, 100 mg/ml streptomycin, 100 IU/ml penicillin, 1% nonessential amino acids, and 10% fetal bovine serum. The Caco-2 cells were allowed to spontaneously differentiate into polarized epithelial cells. The integrity of the differentiated cell monolayers and the tight junctions were monitored before every experiment as previously described (Chang et al., 2007) .
Glucose Uptake Assay. Glucose uptake was performed as previously described using the nonmetabolizable D-glucose analog, AMG, which is a specific substrate for SGLTs (Chang et al., 2007) . Glucose uptake in animals was performed as previously described (Peral et al., 2005) . Briefly, the jejunum was removed, opened longitudinally, and washed with ice-cold normal saline solution. Intestinal segments (1 to 2 cm) of jejunum were incubated at 37°C in a thermostatic bath with continuous shaking in Ringer's solution supplemented with 4 mM AMG and 0.3 mCi/ml D-[ 14 C]-AMG, and continuously bubbled with 95%O 2 /5%CO 2 . At the end of the glucose uptake experiment, the jejunum was washed for 2 minutes with gentle shaking in ice-cold NaClfree Ringer's solution to stop the reaction. The jejunum was then blotted carefully on both sides, and the wet weight of jejunum was measured. The tissue was lysed and extracted by shaking for 15 hours in 1 ml of 0.1 M HNO 3 . The radioactivity levels of all samples were measured using the TopCount NXT liquid scintillation counter (Packard, Meriden, CT). Glucose uptake activity was measured using the SGLT1 specific substrate AMG (Control: n = 6; Rg1: n = 6). (C) The mucosal SGLT1 and b-actin (loading control) protein levels were assessed by western blot. (D) The SGLT1 protein levels in (C) were quantitated (control: n = 6; Rg1: n = 6).
Rg1 Reduces SGLT1 Gene Expression via CREB Deactivation RNA Preparation and Real-Time Quantitative Polymerase Chain Reaction (PCR). The relative levels of SGLT1 transcript were measured using real-time quantitative PCR. The experiments were performed as previously described (Chang et al., 2007) according to the Minimum Information for Publication of Quantitative RealTime PCR Experiments (http://www.rdml.org/miqe.php) guidelines. Briefly, total RNA was prepared using TRIzol reagent (Invitrogen, Carlsbad, CA) from Caco-2 cells or mucosal extracts, obtained by macrodissection. RNA samples (1 mg) were reversed transcribed to cDNA using high-capacity cDNA reverse transcription kits (Applied Biosystems, Foster City, CA). Real-time quantitative PCR analysis was performed using the SYBR Green PCR master mix (Applied Biosystems) on the StepOne real-time PCR system (Applied Biosystems). The sequences of DNA primers for real-time quantitative PCR are listed in Table 1 . The results were obtained from three independent triplicate experimental results and are shown as fold differences in gene transcript level normalized to the endogenous control, glyceraldehyde-3-phosphate dehydrogenase mRNA.
Preparation of the SGLT1 Luciferase Reporter Plasmid. The 1955 base pair fragment of the SGLT1 promoter was amplified by PCR using genomic DNA from human Caco-2 cells and subcloned into the pATL luciferase vector by SpeI and SacII to generate the SGLT1 (21920/122) luciferase construct (Hung et al., 2001) . The sequences of DNA primers for PCR are listed in Table 1 . Subsequently, serial 59-deletions and site mutations of the SGLT1 promoter were generated by PCR to obtain the SGLT1 (21560/122), (2500/122), (2235/122), (2169/122), (2136/122), (283/122), (227/122), and (mutant CRE) luciferase reporter plasmids as previously described (Martin et al., 2000; Wang et al., 2015) . The sequence and orientation of the individual luciferase reporter constructs were confirmed by restriction mapping and DNA sequence analysis.
Transient Transfection and Luciferase Analysis. The cells were seeded into 24-well plates and incubated to 70% confluence before being used for transient transfection. The SGLT1 promoterluciferase reporters were transiently transfected into the cells using the jetPEI transfection reagent (Polyplus Transfection SA, Illkirch, France) and incubated in the presence or absence of Rg1 for 24 hours before being harvested for analysis of luciferase activity. The results are reported as relative luminescence units per microgram protein.
The b-galactosidase activity was used as the internal control to normalize for variations in transfection efficiency by cotransfection with the cytomegalovirus-b-galactosidase reporter. The luciferase activity was normalized to the protein concentration measured using the Pierce BCA Reagent Kit (Rockford, IL).
Western Blot Analysis. The relative level of protein in Caco-2 cells was assessed using western blot as previously described . In animal studies, intestinal mucosa from mice was frozen in liquid nitrogen at the time of removal, as previously described (Huang et al., 2011) . Following homogenization, the tissue samples were lysed and homogenized by sonicating twice for 1 minute. Insoluble materials were removed by centrifugation at 15,000g at 4°C for 30 minutes. The protein samples were collected and subjected to SDS-PAGE and immunoblotted as previously described . The results are presented as the protein-level fold changes normalized to the endogenous b-actin protein level.
Chromatin Immunoprecipitation. The cells were fixed with 1% formaldehyde for 10 minutes at room temperature and then rinsed twice with ice-cold phosphate-buffered saline. The fixed cells were subsequently scraped off the culture dish in a phosphate-buffered saline-containing protease inhibitor mixture and centrifuged at 12,000g for 5 minutes. Cell pellets were resuspended in lysis buffer (0.05M Tris-HCl, pH 8.0, 1% SDS, 0.01M EDTA, and 5 mg/ml sonicated salmon sperm DNA) and sonicated on ice (90 times with a 1-second pulse with a 1-second gap between pulses) using a Misonix 3000 Sonicator (Misonix, Inc., Farmingdale, NY) to obtain DNA fragments (approximately 500 base pairs in size). Immunoprecipitation was performed overnight at 4°C using the appropriate antibodies, followed by incubation with salmon sperm DNA preblocked protein A/G Sepharose beads (Pierce Biotechnology, Rockford, IL). Normal rabbit IgG was used for immunoprecipitation as the negative control reaction. After the samples were eluted and digested with proteinase K, DNA was extracted using phenol/chloroform/IAA (25:24:1) and ethanol precipitation. To analyze specific antibody-bound DNA fractions, PCR was performed using primers to amplify the region in between 2169 and 122 of the SGLT1 promoter as shown in Table 1 . A primer pair to amplify the region of the SGLT1 gene in between 11362 and 11512 was used as the negative control ( Table 1 ). The PCR products were separated by agarose gel electrophoresis and visualized by staining with ethidium bromide.
Lentivirus Small Hairpin RNA (shRNA) Particle Production and Infection. Lentivirus shRNA particles, including shLacZ, shCREB (CREB: TRCN0000226469) and shEGFR (EGFR-1: TRCN0000039634, EGFR-2: TRCN0000121067), were purchased from the National RNAi Core Facility Platform (Taipei, Taiwan). Transduction was performed by incubating the cells with conditioned medium containing lentivirus shRNA particles (Huang et al., 2010a) . The nontransduced cells were eliminated from the culture by incubating cells with 2 mg/ml puromycin for at least 96 hours.
Statistical Analysis. Significant differences among group means were determined by one-way analysis of variance, using SPSS version 11.0 (SPSS, Inc., Chicago) for windows. The calculated P values are indicated in Figures 1-6 (*P , 0.05, **P , 0.01, ***P , 0.001 between the control and Rg1-treated cells or mice).
Results

Rg1 Downregulates SGLT1 Expression in IECs of
Mice. To determine whether Rg1 reduces intestinal absorption of glucose, Rg1 was administered to mice. As shown in Fig. 1B, glucose uptake activity was inhibited in the jejunum from mice that received Rg1. In addition, intestinal SGLT1 expression was also decreased significantly to 0.61-fold compared with control (P , 0.001) in Rg1-treated mice (Fig. 1, C and D). These results indicate that Rg1 reduced SGLT1 gene expression and intestinal glucose uptake in mice. Rg1 Inhibits SGLT1 Expression and Glucose Uptake in Differentiated Human Intestinal Caco-2 Cells. To further investigate whether Rg1 has the capacity to inhibit SGLT1 expression, differentiated human intestinal Caco-2 cells were used. Rg1 reduced SGLT1 protein expression in a time-dependent manner, with evident reduction at 24 hours (0.70-fold, P , 0.05) reaching a minimum level at 48 hours after Rg1 treatment (Fig. 2, A and B) . The results shown in Fig. 2 , C and D also reveal that Rg1 inhibited SGLT1 expression in a dose-dependent manner, with significant reduction from 0.01 to 1mM (from 0.75-to 0.55-fold, respectively, P , 0.01). Consistent with the aforementioned results, glucose uptake activity was also inhibited in a dose-dependent manner in Rg1-treated cells (Fig. 2E) . Next, the effect of Rg1 on the SGLT1 mRNA level was examined. The results shown in Fig. 2 , F and G indicate that Rg1 significantly decreased the SGLT1 mRNA level in both a time-dependent (0.65-fold at 24 hour, P , 0.001) and dose-dependent (0.65-fold with 0.1 mM Rg1; P , 0.01) manner.
Rg1 Transcriptionally Reduces SGLT1 Gene Expression in Differentiated Human Caco-2 Cells. We next examined the kinetic parameter of SGLT1-mediated glucose uptake (Bissonnette et al., 1996) . The result shown in Fig. 3A indicates that Rg1 significantly reduced the maximum velocity (V max ) of glucose uptake (0.61-fold, P , 0.05). In addition, apparent alterations were not seen in the K M of the control and Rg1-treated cells, suggesting that the Rg1-mediated decrease in glucose uptake was likely due to a decreased number of SGLT1 protein molecules.
SGLT1 expression has been shown to be controlled at both the transcription and translation levels as well as the posttranslational levels (Matosin-Matekalo et al., 1998; Loflin and Lever, 2001; Kekuda et al., 2008; Weihua et al., 2008) . To examine the effect of Rg1 on SGLT1 protein or mRNA stability, Caco-2 cells were exposed to the protein synthesis inhibitor, cycloheximide, or the transcription inhibitor, actinomycin D. The results shown in Fig. 3 , B-D indicate that Rg1 displayed no apparent effect on the steady-state level of SGLT1 protein or mRNA in Caco-2 cells.
To determine whether deactivation of SGLT1 promoter is dependent on Rg1, the SGLT1 promoter luciferase construct pATL-SGLT1, which bears the human SGLT1 gene promoter from 21560 to 122, was transfected into Caco-2 cells. As shown in Fig. 3E , Rg1 exhibited significant inhibition on SGLT1 promoter activity in a dose-dependent manner (0.63-fold with 0.1mM Rg1, P , 0.01). These results demonstrated that Rg1-mediated reduction in SGLT1 expression occurred primarily at the transcriptional level since it was faithfully reflected by the SGLT1 gene promoter constructs.
The CRE Is Required for Rg1-Mediated Inhibition of SGLT1 Gene Expression. To study the potential promoter sequence element that is responsible for Rg1-mediated reduction, a series of SGLT1 promoter fragments were constructed, and transiently transfected into Caco-2 cells and incubated in the absence or presence of Rg1. The results shown in Fig. 4A indicate that Rg1 significantly inhibited the transcriptional activity of SGLT1 promoter constructs from 2500/122 to 2136/122, but not the shorter construct 283/122. These results suggest that the Rg1 responsive promoter sequence element is potentially localized in between 2136 and 283. Sequence analysis revealed a putative CRE within this promoter region (Fig. 4B) . Mutation of this putative CRE completely abrogated Rg1-mediated inhibition of SGLT1 promoter activity (Fig. 4C) . These results indicate the critical role of CRE in the inhibitory effect of Rg1.
The chromatin immunoprecipitation assay was next used to validate the binding of CREB and CBP to the CRE. As shown in Fig. 4 , D-F, Rg1 significantly reduced the binding of CREB and CBP factors to the chromatin of the SGLT1 promoter in Caco-2 cells (0.53-and 0.46-fold, P , 0.05 and 0.001, respectively). In addition, Rg1 showed no apparent effect on the binding level of Sp-1 and HNF-1 factors to this region. Since it has been shown that histone acetylation and methylation correlate with the chromatin configuration of the specific gene promoter region, the effect of Rg1 on histone modification of the SGLT1 promoter was examined (Vandel and Trouche, 2001; Yuan and Gambee, 2001; Koch et al., 2007; Rosenfeld et al., 2009 ). The results shown in Fig. 4G indicate that Rg1 conferred a significant decrease in activated chromatin markers (acetyl-histone H3 and dimethylation on lysine 4 of histone H3) and an increase in the repressed chromatin marker (dimethylation on lysine 9 of histone H3) around the SGLT1 promoter region. Taken together, Rg1 reduces the binding of CREB and CBP factors to the SGLT1 promoter and converts the SGLT1 chromatin into an inactivated status.
CREB Inactivation Is Required for Rg1-Reduced SGLT1 Gene Expression. Having shown the decreased CREB binding to the SGLT1 promoter in Rg1-treated cells, the CREB phosphorylation level at Ser133 was examined. The CREB phosphorylation level was significantly reduced in mice treated with Rg1 (0.41-fold, P , 0.001, Fig. 5, A and B) . Further confirmation of Rg1-mediated CREB deactivation was carried out in human Caco-2 cells. As shown in Fig. 5 , C and D, Rg1 markedly decreased the CREB phosphorylation level in a time-dependent manner from 24 to 48 hours (0.81-fold at 24 hours, P , 0.05). To verify that CREB plays an essential role in the Rg1-mediated decrease in the expression of the SGLT1 gene, the CREB gene was stably knocked down in Caco-2 cells using a lentiviral shRNA. As shown in Fig. 5 , E and F, Rg1-mediated reduction in SGLT1 protein expression and glucose uptake was greatly ameliorated in the CREB knockdown cells. These results clearly show that CREB inactivation is required for Rg1-mediated reduction in SGLT1 gene expression.
EGFR/CREB Signaling Pathway Is Essential for Rg1-Mediated Inhibition of SGLT1 Expression. EGFR signaling is known to play an important role in the regulation of SGLT1 gene expression (Mehta et al., 1997; Weihua et al., 2008) . Thus, the effect of Rg1 on the EGFR signaling pathway was investigated. As shown in Fig. 6 , A and B, Rg1 significantly reduced EGFR phosphorylation in a time-dependent manner in Caco-2 cells (0.40-fold at 48 hours, P , 0.001). To confirm the role of EGFR phosphorylation on Rg1-mediated inhibition of SGLT1 expression, EGFR-silenced cells were used. The results shown in Fig. 6 , C and D demonstrate that the Rg1-mediated reduction of SGLT1 protein expression and CREB phosphorylation was abolished in two independent EGFR-silenced cells. Consistent with the aforementioned results, knockdown of EGFR led to Rg1 Reduces SGLT1 Gene Expression via CREB Deactivation The SGLT1 protein expression levels in (A) and (C) were quantitated (n = 3), respectively. (E) Glucose uptake activity was measured using the SGLT1 specific substrate AMG (n = 3). (F) and (G) The SGLT1 mRNA levels were measured by real-time quantitative PCR (n = 3). similar effects on both the SGLT1 mRNA level (Fig. 6E ) and glucose uptake activity (Fig. 6F) . Taken together, these results demonstrate that the EGFR-CREB signaling pathway is crucial for Rg1-mediated reduction of SGLT1 gene expression.
Discussion
Ginsenoside Rg1 is a major and important active compound among the components of ginseng root (Washida and Kitanaka, 2003) . In this study, the concentration range of Rg1 used was submicromolar. At these concentrations, the offtarget effects are minimal compared with most other studies using ginsenosides or triterpenoids (Zhang et al., 2008; Lee et al., 2012a; Gao et al., 2013; Liu et al., 2013) . Previously, it has been known that Rg1 enhances glucose uptake in 3T3-L1 adipocytes and insulin-resistant muscle cells (Huang et al., 2010b; Lee et al., 2012a) . Since the intestine is the site where most nutrients are absorbed, it is interesting to understand the Rg1 Reduces SGLT1 Gene Expression via CREB Deactivation Fig. 4 . Rg1 reduces the binding of CREB and CBP to the CRE in the human SGLT1 promoter and converts the SGLT1 chromatin into an inactivated status. (A) Differentiated Caco-2 cells were transfected with the indicated SGLT1 promoter luciferase reporters in the presence or absence of 0.1 mM Rg1 for 24 hours. The cell lysates were then analyzed for luciferase activity (n = 3). (B) A schematic of the nucleotide sequence of the human SGLT1 promoter region from 2140 to 220 with the CRE, Sp-1, and HNF-1 motif bracketed. (C) The SGLT1 (2500/+22) luciferase reporter with a mutated CRE sequence was transfected into Caco-2 cells that were and incubated with or without 0.1 mM Rg1 for 24 hours. The cell lysates were then analyzed for luciferase activity (n = 3). (D) The differentiated Caco-2 cells were incubated with 0.1 mM Rg1 for 24 hours, and the chromatin immunoprecipitation (ChIP) assays were performed to assess the binding of CREB to the SGLT1 promoter. Total extract (input) was used as a loading control, and immunoprecipitation with irrelevant antibody (anti-IgG) was used as a negative control. A schematic of the SGLT1 genomic region illustrating the CRE and negative control region effect and mechanism of Rg1 in intestinal glucose uptake. Although SGLT1 is the primary glucose transporter in the intestine, it has also been shown that GLUT2 is involved in intestinal glucose absorption in response to high glucose (Kellett et al., 2008) . However, several lines of evidence indicate that GLUT2 is unlikely involved in the inhibitory is shown below. (E) The relative levels of CREB bound specifically to SGLT1 promoter in (D) were quantitated (n = 3). (F) and (G), the ChIP assays were performed as described and to assess the binding of CBP, Sp-1, HNF-1, acetyl-histone H3 (AcH3), dimethylation on lysine 4 of histone H3 (diMeH3K4), and dimethylation on lysine 9 of histone H3 (diMeH3K9) to the SGLT1 promoter. The PCR products were quantitated by densitometry and are presented (n = 3). . CREB dephosphorylation is essential for Rg1-reduced SGLT1 gene expression. Mice were given 20 mg/kg Rg1 orally by gavage and euthanized after 30 hours of administration. (A) Jejunum mucosal extracts were prepared and the protein levels of CREB, phosphorylated CREB (p-CREB), and b-actin (loading control) were assessed by western blot. (B) The protein levels of p-CREB/CREB in (A) were quantitated (n = 3). (C) Caco-2 cells were incubated with or without 0.1 mM Rg1 for the indicated time periods, and the protein levels of CREB, p-CREB, and b-actin (loading control) were assessed by western blot. (D) The p-CREB/CREB levels in (C) were quantitated (n = 3). (E) Caco-2 cells were infected with the indicated shRNA. Caco-2 cells were incubated with or without 0.1 mM Rg1 for 24 hours, and the protein levels of SGLT1, CREB, and b-actin (loading control) were examined by western blot; (F) the glucose uptake assay was measured using the SGLT1 specific substrate AMG (n = 3).
Rg1 Reduces SGLT1 Gene Expression via CREB Deactivation effect of Rg1 in our study, since we have shown that the inhibitory effect of Rg1 on glucose uptake correlates very well with decreased SGLT1 expression levels in the intestines of mice and human intestinal Caco-2 cells (Figs. 1 and 2 ). In addition, our previous results have demonstrated that Rg1 acts primarily on inhibition of SGLT1 gene expression without affecting the GLUT2 levels in Caco-2 cells (Chang et al., 2007) . Our results also showed that Rg1-mediated changes in the maximum velocity of glucose uptake were due to changes in the number of SGLT1 protein molecules. Thus, these results The SGLT1 and p-CREB/CREB levels in (C) were quantitated (n = 3); (E) The SGLT1 mRNA level was measured by real-time quantitative PCR (n = 3). (F) Glucose uptake activity was measured using the SGLT1 specific substrate AMG (n = 3).
evidently indicate that SGLT1 is the primary target of Rg1 for its effect on glucose uptake in our study. It should also be noted that the concentrations of Rg1 used for this in vitro study are within the achievable plasma concentration of Rg1 following oral administration (20 mg/kg; 0.82 mM), based on the oral bioavailability of Rg1 in animal studies (Leung and Wong, 2010) . Taken together, these results provide novel insight into the glucoregulatory activity of ginsenosides, through reduction of intestinal SGLT1 expression.
The evidence shown in the present study demonstrated that Rg1 downregulates glucose uptake primarily through decreased transcription of the SGLT1 gene (Fig. 3, B-E) . The binding elements for transcription factors including Sp-1, HNF-1, and NF-kB were previously recognized as the essential promoter motifs in SGLT1 gene expression in human IECs as well as renal proximal tube cells (Kekuda et al., 2008; Lee et al., 2012b) . Using the luciferase reporter, pATL-SGLT1, with sequential 59-deletions of the SGLT1 promoter, a putative CRE localized within the region of 2136 to 283 was identified and characterized (Fig. 4, A and B) . There are several lines of evidence in this study demonstrating that CRE is essential for the Rg1-mediated inhibition of SGLT1 gene expression. First, the CRE is a consensus CRE motif with no variation in nucleotide sequence and is located at 2132/2121 of the SGLT1 gene promoter, a typical distance for most CREs in different genes (Mayr and Montminy, 2001; Altarejos and Montminy, 2011; Jin et al., 2013) . In addition, mutation in the CRE sequence motif completely blocked Rg1-mediated reduction (Fig. 4C) . Moreover, the chromatin immunoprecipitation assays confirmed that Rg1 caused the decreased binding of phosphorylated CREB and CBP to the CRE-containing promoter region (Fig. 4, D and F) . Furthermore, Rg1 maintains the SGLT1 promoter chromatin in the inactive configuration since the repressed chromatin marker (the dimethylation on lysine 9 of histone H3 level) is increased and both activated chromatin markers (acetyl-histone H3 and dimethylation on lysine 4 of histone H3 levels) are decreased ( Fig. 4G) (Koch et al., 2007; Rosenfeld et al., 2009) . It has been shown that CREB phosphorylation promotes target-gene expression, which recruits its coactivator, CBP/p300, and subsequently acetylates nucleosomal histones (Mayr and Montminy, 2001) . Furthermore, CREB depletion abrogated Rg1-mediated decrease in SGLT1 protein level and glucose uptake (Fig. 5, E and F) . It should be noted that our results revealed a crucial role of CREB in modulating basal SGLT1 gene expression, indicating that the SGLT1 level is reduced by the depletion of CREB (Fig. 5E) or mutation of the CRE sequence (Fig. 4C) . Thus, our finding provides the first evidence showing that Rg1 inhibits SGLT1 gene expression via a CREB-dependent mechanism.
The EGF is produced and secreted from the gastrointestinal tract, which is a heat-and acid-stable peptide (Citri and Yarden, 2006) . Binding of EGF to its receptor (EGFR) leads to the activation of the intrinsic receptor tyrosine kinase, which results in the modulation of multiple cellular processes (Citri and Yarden, 2006) . It is interesting to note that the EGFR signaling pathway has been shown to play a significant role in regulation of SGLT1 gene expression (Mehta et al., 1997; Weihua et al., 2008) . A recent study also reported that activation of EGFR signaling resulted in the increased phosphorylation of CREB in murine NIH3T3 fibroblast cells (Recktenwald et al., 2012) . Here, we show that knockdown of EGFR completely blocks the Rg1-mediated reduction in SGLT1 gene expression, suggesting an essential role of the EGFR pathway in conferring Rg1 activity to SGLT1 gene expression (Fig. 6) . The EGFR Fig. 7 . The proposed mechanism of ginsenoside Rg1-mediated reduction of SGLT1 gene expression and intestinal glucose uptake. Rg1 exert its action through suppression of EGFR phosphorylation and inhibition of the binding of CREB and CBP to the CRE in the SGLT1 promoter, which results in decreased SGLT1 gene expression, and consequently reduced SGLT1-mediated intestinal glucose uptake.
Rg1 Reduces SGLT1 Gene Expression via CREB Deactivation signaling pathway has been shown to be involved in the action of ginsenosides in different mechanisms. A recent study demonstrated that Rg3 reduced the expression of fucosyltransferase IV and its synthetic product Lewis Y, thus suppressing fucosylation, which in turn inhibited the activation of the EGFR/mitogenactivated protein kinase pathway and subsequently prevented melanoma growth (Shan et al., 2015) . Additionally, Rh2 has been shown to induce internalization of lipid rafts and caveolae, which block EGF-stimulated Akt activation and ultimately induce cancer cell apoptosis (Park et al., 2010) . Studies have also shown that the ligand-activated glucocorticoid receptor is essential for the negative regulation of EGFR signaling (Zhang et al., 2007; Lauriola et al., 2014) . In fact, studies have indicated that Rg1 is a functional ligand of the glucocorticoid receptor (Lee et al., 1997; Du et al., 2011) . These findings also suggest the notion that Rg1 might activate the glucocorticoid receptor, which may result in the inhibition of EGFR activation.
It is known that SGLT1 is the primary intestinal glucose transporter that absorbs glucose from the gastrointestinal lumen (Drozdowski and Thomson, 2006) . Several reports have documented increased SGLT1 expression in patients and mice with diabetes (Dyer et al., 1997; Fujita et al., 1998; Dyer et al., 2002) . For example, glucose uptake is enhanced in brushborder membrane vesicles on the duodenum of patients with diabetes and the enhancement is due to increased expression of SGLT1 mRNA and protein levels (Dyer et al., 2002) . It should be noted that the increased circulating glucagon-like peptide-1 level was found in mice and human studies with partial SGLT1 inhibition (Shibazaki et al., 2012; Powell et al., 2013) . Glucagon-like peptide-1 has been shown to normalize fasting hyperglycemia and has been investigated as a potential treatment of diabetes (Meier et al., 2004) . Thus, these findings suggest the notion that partial inhibition of SGLT1 might represent a novel and attractive therapeutic strategy in the treatment of diabetes (Shibazaki et al., 2012) . Natural products provide an important resource in the search for new drugs to prevent metabolic disorders and as new therapeutic approaches (Moller, 2001) . Although ginseng has historically been used in treating diabetes (Sotaniemi et al., 1995; Vuksan et al., 2000) , the detailed mechanism of ginseng-mediated antidiabetic activities is not completely understood. In this study, we present evidence to show that Rg1 inhibited EGFR phosphorylation and reduced CREB and CBP binding to the CRE motif in the human SGLT1 promoter, which resulted in decreased SGLT1 expression and consequently reduced the SGLT1-mediated intestinal glucose uptake (Fig. 7) . Because SGLT1 plays a crucial role in glucose uptake from the lumen in patients with diabetes, our findings provide novel insights into the potential therapeutic relevance of Rg1 in diabetes and hyperglycemia.
